Connect with us
Our website publishes news, press releases, opinion and advertorials on various financial organizations, products and services which are commissioned from various Companies, Organizations, PR agencies, Bloggers etc. These commissioned articles are commercial in nature. This is not to be considered as financial advice and should be considered only for information purposes. It does not reflect the views or opinion of our website and is not to be considered an endorsement or a recommendation. We cannot guarantee the accuracy or applicability of any information provided with respect to your individual or personal circumstances. Please seek Professional advice from a qualified professional before making any financial decisions. We link to various third-party websites, affiliate sales networks, and to our advertising partners websites. When you view or click on certain links available on our articles, our partners may compensate us for displaying the content to you or make a purchase or fill a form. This will not incur any additional charges to you. To make things simpler for you to identity or distinguish advertised or sponsored articles or links, you may consider all articles or links hosted on our site as a commercial article placement. We will not be responsible for any loss you may suffer as a result of any omission or inaccuracy on the website.


Forbius’ AVID200, a novel TGF-beta 1 & 3 Inhibitor, Cleared by the FDA to Commence Phase 1 Clinical Trial in Solid Tumors


Forbius, a clinical-stage company developing biologics for the treatment of cancer and fibrosis, announced today that the U.S. Food and Drug Administration (FDA) has approved its investigational new drug (IND) application to conduct a Phase 1 clinical trial in solid tumors with immuno-oncology candidate AVID200, a rationally designed inhibitor of TGF-beta 1 & 3.

The Phase 1 trial will evaluate safety, pharmacokinetics, pharmacodynamics, and antitumor effects of escalating doses of AVID200. This agent is the Companys second innovative biologic to enter clinical development.

AVID200 is designed to selectively neutralize TGF-beta 1 & 3 with best-in-class pM potency, thus neutralizing the principal immunosuppressive TGF-beta isoforms. AVID200s optimal selectivity is also designed to circumvent cardiac and other safety issues which have limited the applicability of older generation, non-selective TGF-beta inhibitors.

TGF-beta 1 & 3 are the main oncogenic TGF-beta isoforms expressed by many solid tumors. They are believed to play a major role in T-cell suppression, fibrosis, and resistance to immunotherapeutics such as nivolumab (Opdivo) and pembrolizumab (Keytruda) (Chakravarthy et al., Nature Comm., 2018; Tauriello et al., Nature, 2018; Mariathasan et al., Nature, 2018).

AVID200s immuno-oncology mode of action centers on reversal of both immunosuppression and fibrosis in the tumor stroma. In syngeneic mouse tumor models, AVID200 treatment led to T-cell activation, increased immune tumor infiltration, and increased efficacy of immune checkpoint agents.

TGF-beta signaling has emerged as a key target to overcome tumor immunosuppression and resistance to immunotherapies, a major unmet medical need. AVID200 has the potential to significantly expand the number of cancer patients that benefit from checkpoint blockade and other immunotherapies. I am keen to evaluate the effects of AVID200 in this clinical trial, commented Dr. Lillian Siu, a senior medical oncologist and Director of the Phase I Program at Princess Margaret Cancer Centre in Toronto. Dr. Siu is one of the investigators leading the AVID200 Phase 1 study in solid tumors.

About AVID200

AVID200 is positioned to be an effective and well-tolerated therapeutic in a variety of clinical settings being rationally designed to selectively neutralize TGF-beta 1 & 3 with pM potency, thus avoiding TGF-beta 2 related cardiac and hematopoietic toxicity. Overexpression of TGF-beta isoforms 1 & 3 is closely associated with the progression of fibrosis and cancer.

AVID200s immuno-oncology mode of action centers on reversal of immunosuppression as well as a strong anti-fibrotic effect in the tumor stroma. Its development in this setting is supported by the previously announced peer-reviewed BioCanRx grant with a total project value of CAD$1,655,297.

AVID200 is undergoing Phase 1 clinical testing for the treatment of fibrotic diseases and immune oncology.

About Forbius

Forbius is a clinical stage company that designs and develops biotherapeutics for the treatment of cancer and fibrotic diseases. Forbius medicines are designed to radically transform patients lives. We use our strength in biological understanding and diverse protein engineering technologies to design superior inhibitors of validated pathways. We have particularly deep expertise in targeting the transforming growth factor-beta (TGF-beta) and epidermal growth factor receptor (EGFR) pathways. For both of these pathways, there is a significant body of evidence validating their role as drivers of multiple life-threatening conditions, including cancer and fibrosis. However, in the case of the EGFR pathway, the majority of patients do not benefit from currently marketed EGFR inhibitors; in the case of the TGF-beta pathway, no agent targeting this pathway has yet been approved. By using multiple complementary platform technologies, Forbius team overcame barriers that prevented the development of effective therapeutics targeting these pathways. For more information, please visit

Ilia A. Tikhomirov

Editorial & Advertiser disclosure

Call for Entries

Global Banking and Finance Review Awards Nominations 2022
2022 Awards now open. Click Here to Nominate

Newsletters with Secrets & Analysis. Subscribe Now


Global Banking & Finance Review® is a leading financial portal and Print Magazine offering News, Analysis, Opinion, Reviews, Interviews & Videos from the world of Banking, Finance, Business, Trading, Technology, Investing, Brokerage, Foreign Exchange, Tax & Legal, Islamic Finance, Asset & Wealth Management. Copyright © 2010-2021 GBAF Publications Ltd - All Rights Reserved.